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Diﬀ erences in outcome according to Clostridium diﬃ  cile 
testing method: a prospective multicentre diagnostic 
validation study of C diﬃ  cile infection
Timothy D Planche, Kerrie A Davies, Pietro G Coen, John M Finney, Irene M Monahan, Kirsti A Morris, Lily O’Connor, Sarah J Oakley, Cassie F Pope, 
Mike W Wren, Nandini P Shetty, Derrick W Crook, Mark H Wilcox
Summary
Background Diagnosis of Clostridium diﬃ  cile infection is controversial because of many laboratory methods, compounded 
by two reference methods. Cytotoxigenic culture detects toxigenic C diﬃ  cile and gives a positive result more frequently 
(eg, because of colonisation, which means that individuals can have the bacterium but no free toxin) than does the 
cytotoxin assay, which detects preformed toxin in faeces. We aimed to validate the reference methods according to 
clinical outcomes and to derive an optimum laboratory diagnostic algorithm for C diﬃ  cile infection.
Methods In this prospective, multicentre study, we did cytotoxigenic culture and cytotoxin assays on 12 420 faecal 
samples in four UK laboratories. We also performed tests that represent the three main targets for C diﬃ  cile detection: 
bacterium (glutamate dehydrogenase), toxins, or toxin genes. We used routine blood test results, length of hospital 
stay, and 30-day mortality to clinically validate the reference methods. Data were categorised by reference method 
result: group 1, cytotoxin assay positive; group 2, cytotoxigenic culture positive and cytotoxin assay negative; and 
group 3, both reference methods negative.
Findings Clinical and reference assay data were available for 6522 inpatient episodes. On univariate analysis, mortality 
was signiﬁ cantly higher in group 1 than in group 2 (72/435 [16·6%] vs 20/207 [9·7%], p=0·044) and in group 3 
(503/5880 [8·6%], p<0·001), but not in group 2 compared with group 3 (p=0·4). A multivariate analysis accounting for 
potential confounders conﬁ rmed the mortality diﬀ erences between groups 1 and 3 (OR 1·61, 95% CI 1·12–2·31). 
Multistage algorithms performed better than did standalone assays.
Interpretation We noted no increase in mortality when toxigenic C diﬃ  cile alone was present. Toxin (cytotoxin assay) 
positivity correlated with clinical outcome, and so this reference method best deﬁ nes true cases of C diﬃ  cile infection. 
A new diagnostic category of potential C diﬃ  cile excretor (cytotoxigenic culture positive but cytotoxin assay negative) 
could be used to characterise patients with diarrhoea that is probably not due to C diﬃ  cile infection, but who can cause 
cross-infection.
Funding Department of Health and Health Protection Agency, UK.
Introduction
Clostridium diﬃ  cile infection is usually health-care 
associated, is related to antibiotic use, and usually 
manifests as diarrhoea. The infection causes an estimated 
3000 deaths every year in the UK and 15 000–20 000 
deaths in the USA,1,2 with associated case-fatality rates of 
6–17%.3–6 It is associated with the overgrowth of C diﬃ  cile 
and the production of toxins A or B, or both, which cause 
a range of eﬀ ects, including gut mucosal damage, colitis, 
and pseudomembranous colitis.
Since the features of health-care-associated diarrhoea 
cannot reliably distinguish C diﬃ  cile from other causes, 
laboratory conﬁ rmation is essential. However, optimum 
laboratory diagnosis of C diﬃ  cile infection remains 
controversial.7–11 Two reference methods exist: the cell 
cytotoxicity assay, which detects neutralisable toxins; and 
cytotoxigenic culture, which establishes whether cultured 
C diﬃ  cile isolates can produce toxin in vitro. Crucially, the 
reference methods detect diﬀ erent targets, and so 
cytotoxigenic culture might be regarded as having 
inadequate speciﬁ city,9,12 or toxin detection as having 
insuﬃ  cient sensitivity.9,13 However, the signiﬁ cance of a 
positive result with either of these methods is unclear, and 
in turn hinders the clinical interpretation and validation of 
diagnostic methods for C diﬃ  cile infection.12 The availability 
of many commercial tests with diﬀ erent C diﬃ  cile targets is 
both indicative of, and contributes to, uncertainty. The 
widely available assays are C diﬃ  cile toxin A and B enzyme 
immunoassays that detect free toxin in faeces,14,15 glutamate 
dehydrogenase tests that detect a common antigen 
produced by C diﬃ  cile, and nucleic acid ampliﬁ cation tests 
that detect toxin genes but not free toxin.
The performances of C diﬃ  cile toxin enzyme immuno-
assays are inadequate, with positive predictive values 
less than 50% in settings of low disease prevalence.14–16 
Glutamate dehydrogenase assays have been proposed as 
the ﬁ rst step in two-stage algorithms for diagnosis of 
C diﬃ  cile infection,17–20 but their low speciﬁ city makes 
them unsuitable as standalone tests. Several toxin gene 
nucleic acid ampliﬁ cation tests are available, but are also 
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not ideal as standalone tests; they are quite expensive 
(about ﬁ ve to ten times more expensive than enzyme 
immunoassay) and the lower 95% CI for sensitivity is 
roughly 80–85% and that for speciﬁ city is about 93%.12 
Since available diagnostic assays seem to be inadequate 
as standalone tests, several two-stage or three-stage 
algorithms have been proposed.17–21 However, most 
studies comparing C diﬃ  cile tests and algorithms have 
neither assessed each potential target nor used both 
reference methods, and have relied on low sample 
numbers (usually from a single centre), leading to 
unacceptably wide conﬁ dence intervals.17–19,21 A recent 
survey of UK diagnostic laboratories drew attention to 
the absence of consensus about the optimum algorithm 
when it showed that more than 25 diﬀ erent algorithms 
for C diﬃ  cile infection are now in use.22
Imprecise diagnosis has implications for infection 
control practice, patient management, and performance 
management of institutions.7,12 The situation is 
exacerbated because health-care-associated diarrhoea 
often results from causes other than C diﬃ  cile infection, 
including other infections (eg, norovirus), antibiotics, 
laxatives, or surgery. To address these shortcomings, we 
undertook a large observational diagnostic study in four 
routine diagnostic laboratories, in which we used 
routinely submitted diarrhoeal faecal samples. We aimed 
to clinically interpret the reference methods for C diﬃ  cile 
infection, and to assess C diﬃ  cile test performance with 
suﬃ  cient accuracy to compare single assays and establish 
the best possible algorithm for the laboratory diagnosis of 
C diﬃ  cile infection.
Methods
Study design
We did this study in four UK hospital diagnostic 
laboratories serving Leeds Teaching Hospitals NHS 
Trust, St George’s Healthcare NHS Trust, Oxford 
University Hospitals NHS Trust, and University College 
London Hospitals NHS Foundation Trust, and their 
respective communities. The four study hospitals are 
major teaching hospitals, each covering the following 
specialties: general medicine and surgery, elderly 
patients, children, renal, transplant, and oncology. The 
average testing rate in these hospitals was 142·7 tests per 
10 000 patient bed days (range 105–156 per 10 000).
We did all assays on all specimens during a training 
phase (October, 2010–April, 2011). We established the 
optimum algorithm for each reference method and 
carried it forward to the testing phase (May–September, 
2011). We tested samples in the training and testing 
phases with both reference methods. The study was 
approved by the National Research Ethics Service 
(reference number 10/H0715/34).
Samples and procedures
Faecal samples from both hospital and community 
patients submitted for routine testing for C diﬃ  cile 
were eligible for inclusion. We followed the routine 
protocol for sample submission and C diﬃ  cile testing in 
the UK. We tested all unformed faecal samples (Bristol 
stool chart types 5–7, not clearly attributable to an 
underlying disease or treatment) from all hospital 
patients (aged ≥2 years) and from individuals in the 
community (aged ≥65 years), irrespective of C diﬃ  cile 
or other testing requests. Samples were stored at 2–5°C 
and analysed within 5 days. We did all assays at the site 
of submission on unblinded samples.
Methods were standardised across all sites with a 
laboratory manual and standard operating procedures, 
and every evaluator was fully trained in the two reference 
methods before the study began. Cell cytotoxin assay and 
cytotoxigenic culture were done with standard laboratory 
methods. Cell cytotoxin assay was identiﬁ ed by detection 
of cytopathic eﬀ ect on Vero cells, cultured for 48 h, which 
is abolished by antitoxin. Cytotoxigenic culture was done 
after alcohol shock by anaerobic culture on Brazier’s agar 
for 48 h. C diﬃ  cile was then identiﬁ ed and broth cultured 
for a further 48 h and tested for cell cytotoxin (appendix).
For quality assurance, every month one participating 
laboratory, on rotation, sent six blinded samples to the 
other three sites. All assays were undertaken on the 
samples and results compared for inter-laboratory variation.
We assessed tests that represent the three main targets 
for C diﬃ  cile detection: bacterium (glutamate 
dehydrogenase), toxins, or toxin genes. Training was 
provided by assay manufacturers and all tests were done 
according to their instructions. The enzyme immuno-
assays were automated and done on DS2 instruments 
(Magellan Biosciences, North Billerica, MA, USA). We 
assessed the following assays: Meridian Premier toxins 
A&B enzyme immunoassay (toxin enzyme immuno-
assay 1; Meridian Bioscience, Cincinnati, OH, USA); 
Techlab C diﬃ  cile Tox A/B II toxin enzyme immunoassay 
(toxin enzyme immunoassay 2; Techlab, Blacksburg, VA, 
USA); and the Techlab C diﬀ  Chek-60 glutamate 
dehydrogenase enzyme immunoassay (Techlab). The 
nucleic acid ampliﬁ cation test assay was GeneXpert 
(Cepheid, Sunnyvale, CA, USA).
We gathered routinely available patient data as follows: 
blood test results obtained within 3 days of faecal samples 
(white cell count, and serum creatinine and albumin 
concentrations), dates of admission and discharge, age, 
sex, and 30-day all-cause mortality. We obtained baseline 
serum creatinine concentrations from tests done more 
than 6 months before study entry.
We recorded additional data, including computerised 
tomographic evidence of colitis, or if C diﬃ  cile was 
mentioned on a death certiﬁ cate, for patients with positive 
cytotoxigenic culture, cell cytotoxin assay, or nucleic acid 
ampliﬁ cation tests. UK death certiﬁ cates have two 
sections: part 1, cause of death; and part 2, contributing to 
but not causing death. In all cases that were cytotoxigenic 
culture positive and cell cytotoxin assay negative, we 
ascertained the diagnosis of the attending team; whether 
See Online for appendix
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C diﬃ  cile treatment was given; and the duration, 
frequency, and consistency of diarrhoea.
Data were collected, anonymised, and then sent to a 
central coordinator. Data queries were resolved and the 
database was locked on Jan 25, 2012.
Management of C diﬃ  cile infection
Treatment of C diﬃ  cile infection followed standard 
guidelines and remained unchanged during the study. 
Oral metronidazole was given to non-severe cases and oral 
vancomycin to severe cases, with the exception that all 
patients in one centre (Oxford) received oral vancomycin.
Routine laboratory testing methods and reporting for 
C diﬃ  cile continued during the study period. Relevant 
additional positive study results were reported to 
clinicians. Since a cytotoxigenic culture result can take 
up to 5 days to obtain, this test often had little or no eﬀ ect 
on immediate case management.
Analyses
A predeﬁ ned analysis plan categorised patients into 
three groups: group 1, cell cytotoxin assay positive; 
group 2, cytotoxigenic culture positive and cell 
cytotoxin assay negative; and group 3, both cell 
cytotoxin assay and cytotoxigenic culture negative. 
Potential risk factors included were hospital site, age, 
sex, time in hospital before the stool sample was taken, 
albumin con centration lower than 20 g/L, white cell 
count greater than 15 × 10⁹ per L, and a greater than 
50% rise in serum creatinine concentration. Patients 
with any one or more of the following were predeﬁ ned 
to represent severe disease: white cell count greater 
than 15 × 10⁹ per L, a greater than 50% rise in serum 
creatinine concentration, CT or other evidence of 
colitis, and an albumin concentration less than 
20 g per L.
Post-diagnosis survival was deﬁ ned as alive at 
discharge or 30 days after diagnosis (whichever was 
earlier). Since several faecal samples were often 
obtained for every patient, one sample was used per 
episode of diarrhoea, which was deﬁ ned as a diarrhoeal 
sample received more than 28 days after a previous 
sample. For the analysis, we used the ﬁ rst sample 
positive for C diﬃ  cile by either reference method, or the 
ﬁ rst negative sample if no sample was positive. We 
regarded the inpatient time before diarrhoea as a 
potential risk factor for C diﬃ  cile infection.
Statistical analysis
The sample size calculations were made with the 
assumption of an inpatient positivity rate of 4·5%, with 
16% of these patients cytotoxigenic culture positive and 
cell cytotoxin assay negative. We calculated that 
18 000–20 000 samples were needed to detect a 15% 
diﬀ erence in mortality between cell cytotoxin assay 
positive cases and those that were cytotoxigenic culture 
positive but cell cytotoxin assay negative. Preplanned 
interim analysis showed a higher positivity rate (7·5%, of 
which roughly 40% were cytotoxigenic culture positive 
and cell cytotoxin assay negative), which led to a reduction 
in the sample size needed.
For analysis, we used Stata 12·0. We investigated 
univariate trends with t tests and one-way ANOVA, and 
Fisher’s exact test for categorical data. For multivariate 
analysis, we used unconditional logistic regression for 
mortality and parametric survivorship analysis for 
lengths of hospital stay. For survivorship analysis, we 
used the exponential parametric model and censored 
observations at death or discharge (whichever occurred 
ﬁ rst).23 We started with the full model and removed non-
signiﬁ cant variables in a stepwise manner. To assess 
model–data ﬁ t, we used the Hosmer-Lemeshow test.24 To 
investigate excess mortality associated with some 
diagnostic groups we used bootstrap sampling, and 
conﬁ dence intervals were corrected for bias.25
We calculated sensitivity, speciﬁ city, positive 
predictive value, and negative predictive value for single 
assays and combinations of assays (algorithms) in the 
training phase. We analysed all the samples included, 
whether a single patient had several samples or not. 
Interclass correlation coeﬃ  cients and repeat analyses 
on de-duplicated datasets were done (appendix). 
Adequate assay performance was deﬁ ned as greater 
than 90% sensitivity and greater than 99·5% speciﬁ city. 
We established the optimum algorithm for each 
reference method and used this method in the testing 
phase. We used second stage assays only on selected 
samples (those positive in the ﬁ rst assay), and so could 
not calculate sensitivity and speciﬁ city data from this 
dataset. We compared the two reference methods for 
agreement (kappa). Assays and algorithms were 
compared by analysis of area under receiver operator 
characteristics curve (AUROC). For this calculation we 
used Fawcett’s exact method26 and the bootstrap was 
used for calculation of 95% CIs.25 We plotted time series 
to study positivity rates for each assay overall and for 
each participating centre.
12 420 samples analysed from
10 691 episodes
10 186 patients
8026 in-patient results from
6665 episodes
6355 inpatients
Outcome results available for 6522 inpatient episodes
    435 CTA positive
    207 CC positive and negative
5880 both CC and CTA negative
5927 patients survived, 595 patients died
Figure 1: Patient and sample selection
CC=cytotoxigenic culture. CTA=cytotoxin assay.
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Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
12 420 samples were tested from 10 691 diarrhoeal 
episodes in 10 186 patients between Oct 15, 2010, and 
Sept 29, 2011. The training and testing datasets comprised 
6753 and 5667 samples, respectively. 5197 (42%) samples 
were from Leeds, 3852 (31%) from Oxford, 1778 (14%) 
from University College Hospital, and 1593 (13%) from 
St George’s Hospital.
We obtained 8026 results from 6665 episodes in 
6355 inpatients. Outcome data were available for 
6522 inpatient episodes with reference assay results 
available (6283 patients; ﬁ gure 1). Table 1 shows 
baseline characteristics. 926 ﬁ rst samples (either 
inpatient or outpatient) were positive by either 
reference method, 620 were positive by both, 306 by 
cytotoxigenic culture only, and 56 by cell cytotoxin assay 
only (κ 0·739, 95% CI 0·721–0·578). Reference method 
test results were unavailable for two of 6524 patient 
episodes (because of unresolved results). Therefore, 
6522 inpatient episodes with outcome data were 
available for analysis (table 2).
595 deaths were recorded within 30 days. The 30-day 
case all-cause mortality rate was signiﬁ cantly higher in 
group 1 than in groups 2 or 3 (table 2); however, the all-
cause mortality rate did not diﬀ er signiﬁ cantly between 
groups 2 and 3. These data give a rough excess all-cause 
mortality rate of 8% (95% CI 4–11) in patients with a 
positive cell cytotoxin assay. The all-cause mortality rate 
was not signiﬁ cantly higher in group 2 than in group 1. 
Expressed as a death rate per 1000 inpatient days, patients 
in group 1 had signiﬁ cantly higher mortality than did 
those in groups 2 or 3. The death rate did not diﬀ er 
signiﬁ cantly between groups 2 and 3 (table 2).
We did a similar analysis with a nucleic acid 
ampliﬁ cation test as a reference method as a surrogate of 
cytotoxigenic culture. Faecal specimens that were positive 
by nucleic acid ampliﬁ cation testing but negative by cell 
cytotoxin assay were no better predictors of a fatal 
outcome or prolonged length of stay than were cases that 
were cytotoxigenic culture positive and cell cytotoxin 
assay negative (table 3). 
The following predeﬁ ned criteria were used in a 
multivariate logistic regression model with 30-day 
mortality as the dependent factor: diagnostic category 
(group 1, 2, or 3), age older than 65 years, white cell count 
higher than 15 × 10⁹ per L, albumin less than 20 g per L, 
and the hospital where the sample was taken. Compared 
with group 3, group 1 (cell cytotoxin assay-positive 
samples) remained signiﬁ cantly associated with mortality 
(table 4). Bootstrap analysis applied to this multivariate 
model showed signiﬁ cant excess mortality between 
diagnostic groups 1 and 3 (2·95%, 95% CI 0·49–6·07%); 
there was a 35·8% (95% CI 5·83–52·9) excess of deaths in 
positive cases—ie, those attributable to C diﬃ  cile infection. 
All other group comparisons (group 1 vs group 2, and 
group 2 vs group 3) were not signiﬁ cant (data not shown).
Patients in groups 1 and 2 had a longer inpatient stay 
than did those in group 3 before a stool sample was sent to 
the laboratory (table 2). The lengths of stay before and after 
a C diﬃ  cile test (because of diarrhoea) were signiﬁ cantly 
correlated (correlation coeﬃ  cient=0·3353, 95% CI 
0·2810–0·3897). In univariate analysis (table 2), group 3 
patients had a signiﬁ cantly shorter stay in hospital than 
did those in both groups 1 and 2. The diagnostic group or 
the result of the C diﬃ  cile diagnostic tests did not predict 
the length of stay in multivariate logistic regression, 
independently of other predictors (data not shown).
All patients Site 1 Site 2 Site 3 Site 4
Episodes 6665 2635 1368 1092 1570
Inpatients 6355 2560 1280 1025 1490
Female patients 3582/6661 1462/2635 666/1364 592/1092 862/1570
Age (years) 64 (21) 63 (22) 59 (21) 67 (20) 68 (20)
White cell count ×109/L 10·0 (10·3) 10·3 (14·1) 8·8 (6·2) 10·0 (5·5) 10·7 (9·1)
White cell count >15×109/L 940/6204 383/2322 147/1328 143/1056 267/1498
Serum creatinine concentration, μmol/L 106·5 (98·7) 110·9 (91·6) 86·4 (74·7) 106·0 (97·1) 118·0 (123·9)
Rise in serum creatinine concentration (%) 33·9% (85·8) 18·8% (55·9) 6·89% (52·6) 40·9% (93·1) 68·0% (112·6)
Albumin concentration, g/L 32·8 (7·7) 34·7 (6·8) 32·5 (7·6) 26·3 (7·4) 35·1 (6·4)
Albumin <20 g/L 270/5500 21/1908 60/1292 182/968 7/1332
Deaths 595/6524 283/2634 68/1232 125/1088 119/1570
CT positive 615/6663 275/2634 84/1367 99/1092 157/1570
CTA positive 446/6663 236/2634 51/1367 57/1092 102/1570
Data are n, n/N, or mean (SD). The denominators vary in the table because of occasional missing values. Site 1=Leeds Teaching Hospitals NHS Trust. Site 2=University College 
London Hospitals NHS Foundation Trust. Site 3=St George’s Healthcare NHS Trust. Site 4=Oxford University Hospitals NHS Trust. CTA=cytotoxin assay. 
Table 1: Baseline characteristics of inpatients at the four study sites
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Additional data were gathered for 797 samples positive 
for C diﬃ  cile in 710 patients. Of these samples, 446 were 
positive by cell cytotoxin assay, and of the remaining 
351 discordant samples, 176 were positive by both nucleic 
acid ampliﬁ cation test and cytotoxigenic culture, 34 were 
positive by cell cytotoxin assay alone, and 141 were positive 
only by nucleic acid ampliﬁ cation testing. We recorded no 
diﬀ erence in the proportion of patients with signs of 
(predeﬁ ned) severe disease in group 1 and group 2 
(128/247 vs 56/130, p=0·13). We also noted no diﬀ erence 
in disease severity in group 1 patients compared with 
those who were cell cytotoxin assay negative but nucleic 
acid ampliﬁ cation test positive (128/247 vs 85/187, p=0·21).
Death certiﬁ cate data were available for 61 of 92 of the 
fatal cases that were positive by cell cytotoxin assay and 
72 of 102 of those positive by cytotoxigenic culture (or 
nucleic acid ampliﬁ cation test). C diﬃ  cile was mentioned 
in part 1 of more death certiﬁ cates in group 1 than in 
group 2 patients (nine of 39 vs none of 22, p=0·02), and 
in more parts 1 or 2 of group 1 than group 2 patients 
(19/39 vs three of 22, p=0·01). The diﬀ erences remained 
when the analysis was repeated with a comparison of cell 
cytotoxin assay and nucleic acid ampliﬁ cation test results 
(data not shown).
At least some additional clinical data were available in 
143 of 206 inpatients with discordant reference method 
results. Of these patients, 75 who were cytotoxigenic 
culture positive but cell cytotoxin assay negative received 
no treatment for C diﬃ  cile infection, 37 received 
metronidazole, 23 vancomycin, and two both drugs. Of 
the four of 75 cases that were cytotoxigenic culture 
positive and cell cytotoxin assay negative who died and 
Group 1 (CTA positive) Group 2 (CC positive, 
CTA negative)
Group 3 (all negative) Group 1 vs group 2 
p values
Group 1 vs group 3 
p values
Group 2 vs group 3 
p values
n 435 207 5880 ·· ·· ··
Female (%) 243/435 (56%) 118/207 (57%) 3154/5876* (54%) ·· ·· ··
Mean age, (years; SD) 69 (20) 66 (21) 64 (21) ·· ·· ··
Mean white cell count (×109/L; SD) 12·4 (8·9) 10·1 (5·8) 9·9 (10·7) 0·0004 <0·0001 0·6970
Mean rise in creatinine (%; SD) 37% (63) 52% (147) 33% (85) 0·1238 0·2270 0·0028
>100% rise in creatinine (%) 40/316 (13%) 21/169 (12%) 447/4729 (9%) ·· ·· ··
Mean albumin (g/L; SD) 31 (7) 32 (8) 34 (8) 0·5226 <0·0001 0·0017
Albumin <20 g/L (%) 13/344 (4%) 11/166 (7%) 241/4855 (5%) ·· ·· ··
Died (%) 72/435 (16·6%) 20/207 (9·7%) 503/5880 (8·6%) 0·022 <0·0001 0·530
Mean length of stay before sample (days; SD) 18·0 (29) 14·1 (24) 10·7 (21) 0·1584 <0·0001 0·0157
Mean length of stay after sample (days; SD) 19·4 (25) 18·6 (27) 14·2 (22) 0·9498 <0·0001 0·0022
Death rate per 1000 inpatient days 9·03 5·33 6·26 0·0195 0·0033 0·4224
CTA=cytotoxin assay. CC=cytotoxigenic culture. *Sex was not recorded for four patients in this group.
 Table 2: Clinical characteristics of ﬁ rst episodes of inpatients with available clinical outcome results
CTA positive NAAT positive/
CTA negative
CTA and NAAT 
negative
CTA positive vs NAAT 
positive/CTA negative 
p value
CTA positive vs CTA and 
NAAT negative p value
NAAT positive/CTA 
negative vs CTA and 
NAAT negative p value
Number 435 311 3943 ·· ·· ··
Female (%) 243/435 (56%) 174/311 (56%) 2117/3941* (54%) ·· ·· ··
Mean age (years; SD) 69 (20) 64 (22) 64 (21) ·· ·· ··
Mean white cell count (×109/L; SD) 12·4 (8·9) 9·9 (6·6) 10·0 (12·0) <0·0001 <0·0001 0·8633
Mean rise in creatinine (%; SD) 37% (63) 49% (132) 34% (81) 0·0222 0·3018 0·0085
>100% rise in creatinine (%) 40/316 (13%) 30/245 (12%) 321/3163 (9%) ·· ·· ··
Mean albumin (g/L; SD) 31 (7) 33 (8) 33 (8) 0·0328 <0·0001 0·0456
Albumin <20 g/L (%) 13/344 (4%) 15/258 (6%) 166/3223 (5%) ·· ·· ··
Died (%) 72/435 (16·6%) 30/311 (9·7%) 349/3943 (8·9%) 0·004 <0·0001 0·606
Mean length of stay before sample 
(days; SD)
17·9 (29) 13·6 (23) 11·2 (22) 0·0311 <0·0001 0·0978
Mean length of stay after sample 
(days; SD)
19·4 (25) 16·5 (24) 15·1 (24) 0·1869 0·0010 0·2771
Death rate per 1000 inpatient days 9·03 6·04 6·05 0·0317 0·0018 0·8436
CTA=cytotoxin assay. CC=cytotoxigenic culture. NAAT=nucleic acid ampliﬁ cation test.  *Sex was not recorded for two patients in this group. 
Table 3: Clinical characteristics of ﬁ rst episodes of inpatients with available clinical outcome results with use of the result of the CTA and NAAT tests to deﬁ ne diagnostic categories
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did not receive treatment for C diﬃ  cile infection, none 
had a diagnosis of this infection on their death certiﬁ cate. 
Only a few (17/138; 12%) of the patients with a discordant 
reference method result had a recorded clinical diagnosis 
of C diﬃ  cile infection. Furthermore, 64 of 143 (45%) 
patients with a discordant reference method result did 
not have diarrhoea recorded on their stool chart; for the 
remainder of patients, the median duration of diarrhoea 
was 2 days (IQR 1·25–5·5).
12 366 samples had results for cell cytotoxin assay and 
12 402 for cytotoxigenic culture. Of these samples, 
1037 patients had two samples, 199 had three samples, 
66 had four samples, and 21 patients had ﬁ ve or more 
samples. The Xpert assay produced repeat invalid results 
in 26 samples, which were removed from further 
analysis. No other assay produced invalid or indeter-
minate results. The glutamate dehydrogenase and toxin 
enzyme immunoassay 2 tests were not done on 37 and 
33 samples, respectively, because of insuﬃ  cient faeces. 
The toxin enzyme immunoassay 1 and Xpert assays were 
not used ﬁ rst line in the testing phase, and so represent a 
smaller and partially selected dataset (appendix). 
Although we noted a strong correlation between repeat 
samples, this correlation became insigniﬁ cant when the 
analysis was repeated on a duplicated dataset and showed 
no important diﬀ erences between these estimates of 
diagnostic performance and those for the entire real-life 
dataset (appendix).
In the training dataset, no individual assay reached 
both an adequate level of sensitivity and speciﬁ city 
compared with either reference method (appendix). The 
performances of the two toxin enzyme immunoassays 
diﬀ ered substantially, especially in terms of sensitivity 
(appendix); median AUROCs for toxin enzyme 
immunoassay 2 (0·949 [SE 0·0026] and 0·817 [0·0046]) 
were higher than for toxin enzyme immunoassay 1 
(0·906 [0·0035] and 0·791 [0·0050]) compared with cell 
cytotoxin assay and cytotoxigenic culture (both p<0·0001). 
An interim analysis of the training set showed that no 
algorithm or assay was best according to both reference 
methods, although algorithms performed better than 
individual assays (ﬁ gure 2). The optimum algorithm 
compared with cytotoxigenic culture was glutamate 
dehydrogenase enzyme immunoassay–nucleic acid 
ampliﬁ cation test, with 94·6% sensitivity, but speciﬁ city 
was less than 99% (appendix). The combination of toxin 
enzyme immunoassay 2 and nucleic acid ampliﬁ cation 
test was best for reproduction of the cell cytotoxin assay 
result, with a high speciﬁ city but comparatively low 
sensitivity (appendix). Overall, the AUROC was higher 
for two-stage algorithms than for individual assays. The 
performance of glutamate dehydrogenase enzyme 
immunoassay and enzyme immunoassay 2 was almost 
identical to that of toxin enzyme immunoassay combined 
with nucleic acid ampliﬁ cation test (appendix) compared 
with cell cytotoxin assay. We analysed three main 
algorithms in the testing phase that were optimised for 
cytotoxigenic culture (glutamate dehydrogenase–nucleic 
acid ampliﬁ cation test), cell cytotoxin assay (toxin enzyme 
immunoassay–nucleic acid ampliﬁ cation test), or a 
compromise (glutamate dehydrogenase enzyme 
immunoassay–enzyme immunoassay 2).
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Figure 2: AUROCs (median and 95% CI) for each individual assay and 
algorithms
(A) Comparison with the cell cytotoxicity reference method. (B) Comparison 
with the cytotoxigenic culture reference method. Comparisons were done in the 
training phase. Error bars represent 95% CIs. AUROC=area under the receiver 
operator characteristic curve. GDH=glutamate dehydrogenase.
OR (95% CI) p value
Group 1 vs group 3 1·61 (1·12–2·31) 0·0101
Age >65 years 2·52 (1·98–3·21) <0·0001
Site 2 vs site 1 0·48 (0·35–0·67) <0·0001
Site 4 vs site 1 0·54 (0·41–0·72) <0·0001
WCC >15 × 109/L 1·94 (1·52–2·47) <0·0001
>50% rise in serum creatinine 2·25 (1·69–2·99) <0·0001
Serum albumin <20 g/L 2·72 (1·90–3·91) <0·0001
OR=odds ratio. WCC=white cell count.
Table 4: Multivariate logistic regression analysis with 30-day mortality 
as the dependent factor
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The poor performance of the individual assays was 
conﬁ rmed when the training and testing datasets were 
combined (table 5). As in the training set, the optimum 
algorithm to reproduce cytotoxigenic culture was 
glutamate dehydrogenase enzyme immunoassay–
nucleic acid ampliﬁ cation test, but this algorithm had 
speciﬁ city less than 98·0%. Toxin enzyme immunoassay 
2–nucleic acid ampliﬁ cation test and glutamate 
dehydrogenase enzyme immunoassay–toxin enzyme 
immunoassay 2 were almost identical in performance to 
cell cytotoxin assay (table 5).
Discussion
We clinically validated the laboratory diagnosis of 
C diﬃ  cile infection according to established but divergent 
reference methods in the largest diagnostic study of this 
disease so far (panel). Diarrhoea is a common symptom 
but is rarely due to C diﬃ  cile.7 We noted that more than 
90% of diarrhoeal samples submitted had no evidence of 
C diﬃ  cile infection. However, the 30-day all-cause 
mortality rate was higher than 8% in patients with 
diarrhoea, indicating a group with severe underlying 
disease. The presence of cytotoxigenic C diﬃ  cile in faeces 
of asymptomatic patients varies from roughly 2% in the 
general population28,29 to up to 7–25% of patients admitted 
to hospital.30,31 Thus, patients carrying C diﬃ  cile only as a 
”bystander” (ie, asymptomatically colonised patients) 
who develop health-care-associated diarrhoea for other 
reasons would have a comparatively high case-fatality 
rate, which would necessitate a large validation study.
We noted a higher case-fatality rate in cases that were 
cell cytotoxin assay positive (group 1) than in those that 
were cytotoxigenic culture positive and cytotoxin assay 
negative (group 2) and those that were negative by both 
reference methods (group 3). Patients with a positive 
cytotoxigenic culture but negative cell cytotoxin assay had 
the same case-fatality rate as did C diﬃ  cile-negative cases; 
indeed, their fatality rate per 1000 bed days was not 
signiﬁ cantly lower than that noted for C diﬃ  cile-negative 
patients. These results indicate that C diﬃ  cile infection is 
conﬁ rmed by a positive cell cytotoxin assay and not by 
cytotoxigenic culture, which supports the ﬁ ndings of 
earlier smaller studies32,33 but contrasts with others.34 
Diﬀ erences in case-fatality rates between sites (tables 1 
and 4) are probably attributable to diﬀ erences in case 
mixes and endorse the need for a large multicentre study. 
Although most deaths were in patients with negative tests 
for C diﬃ  cile, and so were unrelated to C diﬃ  cile infection, 
the presence of toxin in faecal samples was still associated 
with a fatal outcome in multivariate analysis. Since many 
patients without C diﬃ  cile have several comorbidities, we 
could not diﬀ erentiate between patients on the basis of 
our predeﬁ ned markers of severity.
The two reference methods provide diﬀ erent 
information. A positive cell cytotoxin assay indicates that 
the diarrhoea was probably caused by C diﬃ  cile infection, 
whereas a positive cytotoxigenic culture indicates that a 
patient could be infectious even though the diarrhoea 
might have resulted from another cause. Since we 
recorded no evidence of ongoing carriage, we propose 
the term ”potential C diﬃ  cile excretor” for patients with 
samples that are cytotoxigenic culture positive but cell 
cytotoxin assay negative. By analysis of cases with 
discordant reference method results, we showed that 
poor outcome correlated with detectable toxin as opposed 
to the presence of C diﬃ  cile with toxigenic potential, 
whether or not speciﬁ c C diﬃ  cile infection treatment was 
given. Since the median duration of diarrhoea was 2 days 
in these patients, most symptoms probably resolved 
before cytotoxigenic culture results were available, with 
treatment considered unnecessary. Our ﬁ ndings indicate 
the need to treat patients who are positive for C diﬃ  cile 
toxin. The management of potential C diﬃ  cile excretors is 
less clear, but, because they might be infectious, infection 
control precautions should be taken. When C diﬃ  cile 
infection is excluded, other causes of diarrhoea should be 
sought. We caution, however, that the need for C diﬃ  cile 
infection treatment is a clinical decision, which might be 
improved with clinical interpretation of a result,35 in view 
of the suboptimum sensitivity of existing assays.14,15 Since 
Cytotoxigenic culture Cytotoxin assay
GDH EIA Toxin*EIA 1 Toxin EIA 2 GDH EIA 
NAAT
Toxin EIA 2 
NAAT
GDH toxin 
EIA 2
GDH EIA Toxin†EIA 1 Toxin EIA 2 GDH EIA 
NAAT
Toxin EIA 2 
NAAT
GDH toxin 
EIA 2
Sensitivity 
(%; 95% CI)
94·5% 
(92·9–95·8)
45·6% 
(42·0–49·1)
58·0% 
(55·0–61·1)
91·5% 
(89·6–93·1)
57·8% 
(54·8–60·9)
57·0% 
(53·9–60·0)
96·4% 
(94·8–97·7)
66·9% 
(62·7–70·8)
83·2% 
(80·3–85·8)
95·6% 
(93·9–97·0)
82·9% 
(80·0–85·6)
81·8% 
(78·8–84·5)
Speciﬁ city 
(%; 95% CI)
94·5% 
(94·1–94·9)
99·2% 
(99·0–99·4)
98·7% 
(98·4-98·9)
98·0% 
(97·7–98·3)
99·5% 
(99·3–99·6)
99·4% 
(99·3–99·6)
92·2% 
(91·7–92·7)
99·3% 
(99·1–99·5)
98·8% 
(98·6–99·0)
95·9% 
(95·6-96·3)
99·6% 
(99·4–99·7)
99·5% 
(99·4–99·6)
PPV (%; 95% CI) 61·0% 
(58·6–63·4)
84·5% 
(80·7–87·8)
80·0% 
(77·0–82·8)
80·7% 
(78·3–82·9)
90·7% 
(88·3–92·8)
90·1% 
(87·5–92·2)
43·9% 
(41·4–46·3)
86·4% 
(82·8–89·6)
81·2% 
(78·2–83·9)
59·7% 
(56·8–62·5)
92·1% 
(89·8–94·0)
91·6% 
(89·2–93·6)
NPV (%; 95% CI) 99·5% 
(99·3–99·6)
95·2% 
(94·7–95·6)
96·3% 
(95·9–96·6)
99·2% 
(99·0–99·4)
96·3% 
(95·9–96·6)
96·2% 
(95·8–96·5)
99·8% 
(99·6–99·8)
97·9% 
(97·6–98·2)
98·9% 
(98·7–99·1)
99·7% 
(99·6–99·8)
98·9% 
(98·7–99·1)
98·9% 
(98·7–99·0)
n=12 420, although small variations in n for each test or algorithm are shown in the appendix. GDH=glutamate dehydrogenase. EIA=enzyme immunoassay. NAAT=nucleic acid ampliﬁ cation test. PPV=positive 
predictive value. NPV=negative predictive value. *n=9191 because some centres continued to use the assay in the testing phase. Per-protocol version is in the appendix. †n=9160 because some centres 
continued to use the assay in the testing phase. Per-protocol version is in the appendix.
Table 5: Sensitivity and speciﬁ city of individual assays and algorithms compared with both reference methods
www.thelancet.com/infection   Vol 13   November 2013 943
Articles
only 25% of cases of C diﬃ  cile infection could be matched 
with previous cases,36 the sources of C diﬃ  cile in some of 
the remaining unexplained cases could be patients who 
are colonised by toxigenic strains. These patients could 
be asymptomatic or, as we identiﬁ ed, patients with 
diarrhoea not due to C diﬃ  cile infection (ie, potential 
C diﬃ  cile excretors). However, since these tests are not 
being used as screening tests, we cannot be sure how 
much of an eﬀ ect the identiﬁ cation of C diﬃ  cile-colonised 
patients would have on C diﬃ  cile transmission rates in 
hospitals.
In the UK, the long-standing policy is to take samples 
from all patients with diarrhoea, even after only one or 
two episodes, and more tests for C diﬃ  cile infection are 
done than in other European countries.37 Outcome data 
were nearly complete, and although the data available for 
secondary endpoints such as treatment were available in 
60–70% of cases, the results seem robust. As an 
observational study, the strong associations shown here 
do not conﬁ rm causality. However, the fact that patients 
who were cytotoxigenic culture positive but cell cytotoxin 
assay negative had good outcomes, despite not receiving 
any speciﬁ c treatment for C diﬃ  cile infection, strongly 
suggests a causal link between outcome and cell cytotoxin 
assay positivity.
For convenience, most diagnostic laboratories do not 
use reference methods. However, the performance of 
routine C diﬃ  cile diagnostic tests is established by 
comparing them to reference methods. Our data 
emphasise the need to choose the appropriate reference 
method for each test. This multicentre study draws 
attention to geographical variation in test performance 
(appendix) and conﬁ rms previous study ﬁ ndings of 
poor positive predictive values for toxin enzyme 
immunoassays.14,15
The sensitivities of the standalone glutamate 
dehydrogenase enzyme immunoassay and Xpert nucleic 
acid ampliﬁ cation test were not as high as have been 
previously reported.17–20 However, the large sample size in 
this study has produced a more accurate result with 
narrower conﬁ dence intervals. The negative predictive 
values of these two assays were greater than 99% 
compared with either reference method, but positive 
predictive values were less than 75%, at best (appendix). 
Although the Xpert nucleic acid ampliﬁ cation test detects 
only toxigenic C diﬃ  cile, unlike the glutamate dehydro-
genase assay, the poor positive predictive values that we 
noted indicate that this assay should not be used alone to 
diagnose C diﬃ  cile infection. Therefore, our data 
contradict a recent recommendation by Surawicz and 
colleagues38 to use a nucleic acid ampliﬁ cation test alone. 
Indeed, cases of C diﬃ  cile infection diagnosed by this test 
alone have been shown to be signiﬁ cantly less likely to be 
associated with complications than those diagnosed by a 
combination of nucleic acid ampliﬁ cation test and toxin 
assay.27 Notably, laboratory diagnosis by nucleic acid 
ampliﬁ cation test as opposed to detection of toxin (cell 
cytotoxin assay), according to our data would yield 81% 
(95% CI 77–85) more positive results. The longer 
turnaround times and high cost of two-stage algorithms 
have led some researchers to advocate nucleic acid 
ampliﬁ cation test alone despite the potential 
disadvantages.11,12,38 Our results show that two-stage 
algorithms can improve the accuracy of diagnosis of 
C diﬃ  cile infection (ﬁ gure 2). The positive predictive 
values and negative predictive values of the algorithms 
will vary dependent on the prevalence of C diﬃ  cile 
infection in the samples tested. However, standalone 
tests would be unlikely to have acceptable performance 
unless the prevalence is very high (>40%; appendix).
Since the two reference methods are clearly not 
comparable, no single algorithm could be optimised for 
both. Glutamate dehydrogenase enzyme immunoassay–
nucleic acid ampliﬁ cation test and toxin enzyme 
immunoassay 2–nucleic acid ampliﬁ cation test best 
reproduced cytotoxigenic culture and cell cytotoxin 
assay, respectively. Since the clinical implications of a 
Panel: Research in context
Background
The clinical interpretation of tests for C diﬃ  cile infection is confused by uncertainty about 
which of the two reference methods correlates best with clinical outcome. We have done 
the largest study of its type to validate the most clinically appropriate reference method 
for C diﬃ  cile infection. This issue has previously been addressed only in small studies.25,26 
Typically, studies of C diﬃ  cile diagnostic tests have not included clinical outcome 
measures, and thus positive results are assumed to correlate with true disease.9,12,15
Interpretation
We have shown that in more than 6000 patients with diarrhoea, no increase in mortality 
occurred when a toxigenic C diﬃ  cile strain alone was present (cytotoxigenic culture 
positive, cell cytotoxin assay negative). By contrast, toxin (cell cytotoxin assay) positivity 
was associated with clinical outcome, and so this reference method best deﬁ nes true cases 
of C diﬃ  cile infection. Other clinical indicators were worse for cell cytotoxin assay-positive 
cases, but noted no diﬀ erence between cytotoxigenic culture-positive, cell cytotoxin 
assay-negative cases, and negative controls.
For the ﬁ rst time, we have described a new diagnostic category of potential C diﬃ  cile 
excretors (cytotoxigenic culture positive and cell cytotoxin assay negative) to characterise 
patients with diarrhoea that is unlikely to be due to C diﬃ  cile infection, but who 
nevertheless can cause cross-infection. No single assay adequately reproduced either 
reference method as a standalone test. Consequently, we identiﬁ ed C diﬃ  cile infection test 
algorithms that are optimised according to either cytotoxigenic culture results 
(glutamate dehydrogenase–nucleic acid ampliﬁ cation test) or cell cytotoxin assay results 
(enzyme immunoassay 2–nucleic acid ampliﬁ cation test). A compromise solution to 
C diﬃ  cile infection testing is to use glutamate dehydrogenase (or nucleic acid 
ampliﬁ cation test–toxin enzyme immunoassay 2). In so doing, a highly sensitive ﬁ rst-
stage C diﬃ  cile test (glutamate dehydrogenase or nucleic acid ampliﬁ cation test) allows 
detection of patients colonised by C diﬃ  cile (but without free toxin), whereas the second 
more speciﬁ c test, which needs to be done only on a few faecal samples, identiﬁ es those 
likely to have C diﬃ  cile infection. Importantly, in agreement with a recent single-centre 
study,27 we reported that use of a nucleic acid ampliﬁ cation test alone leads to over-
diagnosis of C diﬃ  cile infection, as evidenced by an absence of association with mortality 
and C diﬃ  cile infection-related complications.
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positive cytotoxigenic culture and cell cytotoxin assay 
diﬀ er, to undertake both of these algorithms is complex 
and expensive. However, another algorithm (glutamate 
dehydrogenase enzyme immunoassay–toxin enzyme 
immunoassay 2) performed almost identically to toxin 
enzyme immunoassay 2–nucleic acid ampliﬁ cation test 
in prediction of cell cytotoxin assay. This algorithm has 
the advantage that it allows the stratiﬁ cation of results 
into three categories: C diﬃ  cile infection positive, 
potential C diﬃ  cile excretor, and C diﬃ  cile infection 
negative. This advantage allows rapid reporting of about 
86% of results as glutamate dehydrogenase negative, 
which has important implications for infection control; 
the high negative predictive value (99·5% for 
cytotoxigenic culture and and 99·8% for cell cytotoxin 
assay; table 5) associated with this test means that 
C diﬃ  cile infection can be excluded with a high degree of 
certainty. Then reﬂ ex testing for toxin enzyme 
immunoassay allows the identiﬁ cation of samples that 
are cell cytotoxin assay positive, with a sensitivity of just 
above 80%. The remaining samples with discordant 
results (glutamate dehydrogenase enzyme immuno-
assay positive/toxin enzyme immunoassay negative)—
about 8% of samples in this study—can then be 
managed. In our sample, about 60% of these cases were 
negative, 30% potential C diﬃ  cile excretors, and 10% 
positive for cell cytotoxin assay. These discordant cases 
can be treated as negative or potential C diﬃ  cile excretors, 
despite the relatively low positive predictive value. The 
ﬁ nal possibility is to do a nucleic acid ampliﬁ cation test 
on these discordant samples to clearly identify potential 
C diﬃ  cile excretors. The three-stage strategy eﬀ ectively 
combines the detection of cell cytotoxin assay and 
cytotoxigenic culture into one algorithm.
Notwithstanding the size of this study and completeness 
of the follow-up, the reproduction of real-life testing in 
diagnostic laboratories in England has potential 
limitations, in addition to its strengths. This trial was an 
observational study in which the laboratory workers were 
not masked to results. However, in view of the time taken 
to obtain results for the reference methods and the length 
of follow-up, the results were unlike to have aﬀ ected, or to 
have been aﬀ ected by, the results of tests done on day 1. 
The other serendipitous result of waiting for several days 
for results of culture was that many patients who were 
positive only by cytotoxigenic culture were not treated for 
C diﬃ  cile infection, which helps to conﬁ rm the safety of 
this strategy when undertaken with clinical supervision. 
The frequency of stool sampling and testing was high. 
The application of these ﬁ ndings to health-care settings 
in which testing is less frequent and needs to be requested 
by physicians is uncertain. The strategy of testing only 
physician-requested samples certainly misses many cases 
of C diﬃ  cile infection.39 To imagine how a diﬀ erent 
selection of cases to sample or test for C diﬃ  cile infection 
would aﬀ ect the clinical meaning of the reference 
methods is diﬃ  cult.
We have shown that detection of toxin is an essential 
step in the diagnosis of C diﬃ  cile infection. The 
importance of toxin detection, and also the deﬁ ciencies 
of existing tests, should drive further assay development. 
We have identiﬁ ed the best possible algorithm for 
C diﬃ  cile infection diagnosis that also identiﬁ es potential 
C diﬃ  cile excretors. Further investigation is needed to 
establish the clinical implications of such patients, 
including their infection risk to others and their optimum 
management.
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